Qiagen In Crisis, Previews Poor Q3 Sales; Long-Term CEO Steps Down
Qiagen shares took a hit following a series of negative announcements, including lower than expected results for Q3 2019 and the departure of long-term CEO Peer Schatz. The company said it had been affected by poor sales growth in China.
You may also be interested in...
Hedge fund Davidson Kempner advised Qiagen to ask for a higher acquisition price from Thermo Fisher Sciences as COVID-19 has increased demand for diagnostic products.
Thermo Fisher expects the deal to improve its portfolio of specialty diagnostics for clinical labs while its genetic analysis technologies, biosciences reagents and consumable products will complement Qiagens’ sample preparation and assay technologies.
Qiagen official Antoine Marchal outlines how NeuModx will strengthen its position in the infectious disease space.